UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1), p.420-420, Article 420

2016

Volltextzugriff (PDF)

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

BMC cancer, 2016-07, Vol.16 (1)

2016

Volltextzugriff (PDF)

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

British journal of cancer, 2007-04, Vol.96 (7), p.1013-1019

2007

Volltextzugriff (PDF)

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

British journal of cancer, 2007-08, Vol.97 (3), p.315-321

2007

Volltextzugriff (PDF)

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

Bone marrow transplantation (Basingstoke), 2009-03, Vol.43 (5), p.383-397

2009

Volltextzugriff (PDF)

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

Bone marrow transplantation (Basingstoke), 2009-03, Vol.43 (5), p.383-397

2009

Volltextzugriff (PDF)

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

British journal of cancer, 2000-07, Vol.83 (2), p.261-266

2000

Volltextzugriff (PDF)

Influence of Catumaxomab on Tumor Cells in Bone Marrow and Blood in Ovarian Cancer

Anticancer research, 2009-05, Vol.29 (5), p.1787-1791

2009

Volltextzugriff (PDF)

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies ({{alpha}}EpCAM {{alpha}}CD3)

The journal of histochemistry and cytochemistry, 2001-07, Vol.49 (7), p.911-917

2001

Volltextzugriff (PDF)

2010P Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study

Annals of oncology, 2024-09, Vol.35, p.S1160-S1160

2024

Volltextzugriff (PDF)

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes

International journal of oncology, 2004-10, Vol.25 (4), p.841

2004

Volltextzugriff (PDF)

8007 ORAL Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment

European journal of cancer (1990), 2011, Vol.47, p.S529-S529

2011

Volltextzugriff (PDF)

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

Blood, 2001-10, Vol.98 (8), p.2526-2534

2001

Volltextzugriff (PDF)

Combined Treatment of Metastatic Breast Cancer (MBC) by High-dose Chemotherapy (HDCT) and Bispecific Antibodies: A Pilot Study

Anticancer research, 2005-07, Vol.25 (4), p.3047-3054

2005

Volltextzugriff (PDF)

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma

Annals of oncology, 2006-12, Vol.17 (12), p.1830-1834

2006

Volltextzugriff (PDF)

Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy

European urology open science (Online), 2022-11, Vol.45, p.S234-S235

2022

Volltextzugriff (PDF)

1313 Catumaxomab treatment reduces VEGF protein levels within malignant ascites: data from a pivotal phase II/III study

European journal of cancer supplements, 2009, Vol.7 (2), p.142-143

2009

Volltextzugriff (PDF)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer

Journal of Gynecologic Oncology, 2014, 25(3), , pp.221-228

2014

Volltextzugriff (PDF)

1312 Catumaxomab therapy eliminates putative CD133+ EpCAM+ cancer stem celles from malignant ascites: data from a pivotal phase II/III study

European journal of cancer supplements, 2009, Vol.7 (2), p.142-142

2009

Volltextzugriff (PDF)

6507 Catumaxomab treatment in gastric-cancer patients with malignant ascites – subgroup-analysis of a pivotal trial

European journal of cancer supplements, 2009, Vol.7 (2), p.363-363

2009

Volltextzugriff (PDF)

Immunotherapy of malignant ascites with trifunctional antibodies

International journal of cancer, 2005-11, Vol.117 (3), p.435-443

2005

Volltextzugriff (PDF)

Lasting remission following multimodal treatment in a patient with metastatic breast cancer

Anti-cancer drugs, 2005-11, Vol.16 (10), p.1135-1137

2005

Volltextzugriff (PDF)

Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

International journal of gynecological cancer, 2013-06, Vol.23 (5), p.797-802

2013

Volltextzugriff (PDF)

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes

Blood, 2006-02, Vol.107 (4), p.1564-1569

2006

Volltextzugriff (PDF)

Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

The Journal of immunology (1950), 1999-08, Vol.163 (3), p.1246-1252

1999

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(91)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(103)
Tagungsberichte
(6)

Sprache

Englisch
(83)
Deutsch
(26)
Polnisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(41)
Life Sciences & Biomedicine
(29)
Science & Technology
(29)
Middle Aged
(24)
Female
(21)
Male
(21)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Oncology
(18)
Immunotherapy
(16)
Adult
(15)
Animals
(13)
Mice
(13)
Tumors
(11)
Antineoplastic Agents
(10)
Lipoproteins - Blood
(10)
Pharmacology. Drug Treatments
(10)
Aged
(9)
Antibodies, Bispecific - Therapeutic Use
(9)
Cholesterol - Blood
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors

EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

Influence of Catumaxomab on Tumor Cells in Bone Marrow and Blood in Ovarian Cancer

Lysis of Prostate Carcinoma Cells by Trifunctional Bispecific Antibodies ({{alpha}}EpCAM {{alpha}}CD3)

2010P Trifunctional anti-EpCAM/CD3 bsAb catumaxomab intravesically for high and intermediate risk non muscle invasive bladder cancer (HMR-NMIBC): Interim analysis of a phase I study

Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes

8007 ORAL Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment

Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody

Combined Treatment of Metastatic Breast Cancer (MBC) by High-dose Chemotherapy (HDCT) and Bispecific Antibodies: A Pilot Study

Increased chondroitin sulphate proteoglycan expression (B5 immunoreactivity) in metastases of uveal melanoma

Results of phase I dose escalation of the trifunctional anti-EpCAM/CD3 bsAb Catumaxomab in intravesical therapy of high risk non muscle invasive bladder cancer (HR-NMIBC): Excellent tolerability and encouraging preliminary efficacy

1313 Catumaxomab treatment reduces VEGF protein levels within malignant ascites: data from a pivotal phase II/III study

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer

1312 Catumaxomab therapy eliminates putative CD133+ EpCAM+ cancer stem celles from malignant ascites: data from a pivotal phase II/III study

6507 Catumaxomab treatment in gastric-cancer patients with malignant ascites – subgroup-analysis of a pivotal trial

Immunotherapy of malignant ascites with trifunctional antibodies

Lasting remission following multimodal treatment in a patient with metastatic breast cancer

Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes

Simultaneous Activation of T Cells and Accessory Cells by a New Class of Intact Bispecific Antibody Results in Efficient Tumor Cell Killing

Suchergebnisse filtern